Article Versions Notes

Takano M, Toda S, Watanabe H, Fujimura R, Nishida K, Bi J, Minayoshi Y, Miyahisa M, Maeda H, Maruyama T. Engineering of a Long-Acting Bone Morphogenetic Protein-7 by Fusion with Albumin for the Treatment of Renal Injury. Pharmaceutics. 2022; 14(7):1334. https://doi.org/10.3390/pharmaceutics14071334

Takano, Mei, Shota Toda, Hiroshi Watanabe, Rui Fujimura, Kento Nishida, Jing Bi, Yuki Minayoshi, Masako Miyahisa, Hitoshi Maeda, and Toru Maruyama. 2022. "Engineering of a Long-Acting Bone Morphogenetic Protein-7 by Fusion with Albumin for the Treatment of Renal Injury" Pharmaceutics 14, no. 7: 1334. https://doi.org/10.3390/pharmaceutics14071334

Takano, M., Toda, S., Watanabe, H., Fujimura, R., Nishida, K., Bi, J., Minayoshi, Y., Miyahisa, M., Maeda, H., & Maruyama, T. (2022). Engineering of a Long-Acting Bone Morphogenetic Protein-7 by Fusion with Albumin for the Treatment of Renal Injury. Pharmaceutics, 14(7), 1334. https://doi.org/10.3390/pharmaceutics14071334